4
Changes in Ownership
Atara Biotherapeutics, Inc. Filed Acc 0001209191-18-021991
EVP & Chief R & QA Officer sold 100,203 shares at an average $37.87 ($3,795,062)
- EVP & Chief R & QA Officer acquired 72,754 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Clark Mitchall G. · EVP & Chief R & QA Officer
Table I: Non-derivative
9 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2018-03-27 | Exercise or conversion : show line 1 in the form | +28,848 | $25.15 | $725,527 | 212,368 | D |
| 2018-03-27 | Exercise or conversion : show line 2 in the form | +32,500 | $22.72 | $738,400 | 244,868 | D |
| 2018-03-27 | Exercise or conversion : show line 3 in the form | +11,406 | $11.00 | $125,466 | 256,274 | D |
| 2018-03-27 | Sale : show line 4 in the form | −22,794 | $36.43 | $830,385 | 233,480 | D |
| 2018-03-27 | Sale : show line 5 in the form | −31,356 | $37.10 | $1,163,308 | 202,124 | D |
| 2018-03-27 | Sale : show line 6 in the form | −29,980 | $38.23 | $1,146,135 | 172,144 | D |
| 2018-03-27 | Sale : show line 7 in the form | −2,170 | $39.53 | $85,780 | 169,974 | D |
| 2018-03-27 | Sale : show line 8 in the form | −2,800 | $40.40 | $113,120 | 167,174 | D |
| 2018-03-27 | Sale : show line 9 in the form | −11,103 | $41.10 | $456,333 | 156,071 | D |
| Open-market sales · 100,203 sh · avg $37.87 · $3,795,062 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2018-03-27 | Exercise or conversion : show line 10 in the form Employee Stock Option (Right to Buy) | −28,848 | 11,194 | D |
| 2018-03-27 | Exercise or conversion : show line 11 in the form Employee Stock Option (Right to Buy) | −32,500 | 32,500 | D |
| 2018-03-27 | Exercise or conversion : show line 12 in the form Employee Stock Option (Right to Buy) | −11,406 | 3,125 | D |
Loading xslF345X03/doc4.xml…